Search
Sioux Falls, SD Paid Clinical Trials
A listing of 276 clinical trials in Sioux Falls, SD actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
253 - 264 of 276
There are currently 276 clinical trials in Sioux Falls, South Dakota looking for participants to engage in research studies. Trials are conducted at various facilities, including Sanford USD Medical Center - Sioux Falls, Avera Cancer Institute, Sanford Cancer Center Oncology Clinic and Sanford Cancer Center at Sanford USD Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Featured Trial
Major Depressive Disorder Clinical Study
Recruiting
Is depression weighing you down? Local major depressive disorder clinical studies are now enrolling participants in the area. Participating in research studies helps contribute to the advancement of future medicine and treatment options. There is no obligation to take part and health insurance is not required.
Conditions:
Major Depressive Disorder
Major Depression
Major Depressive Episode
Major Depressive Disorder (MDD)
Major Depressive Disorders
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Irritability Associated with Autism (Children and Adolescents) Study
Recruiting
Join a clinical trial today and take a step toward finding a better solution for you. Earn money for your time and no-cost medical treatment is provided.
Featured Trial
Child/Teen Migraine Study
Recruiting
Become part of a clinical trial today and play a role in driving medical research forward, aiding in the discovery of groundbreaking therapies. Get rewarded for your time with monetary compensation and enjoy access to medical treatment at no charge.
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Recruiting
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spread... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2023
Locations: Avera Cancer Institute, Sioux Falls, South Dakota
Conditions: Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2023
Locations: Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota +2 locations
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Maternal Stress and Blood Sugar Metabolization
Recruiting
During pregnancy, gestational diabetes increases the risk of complications and adverse outcomes for mother and child, however about 50% of gestational diabetes cases are diagnosed without a known risk factor present. This project uses both a large sample retrospective study, and a prospective study to help us understand the mechanisms by which mental health and stress impact glucose metabolization during pregnancy and delineate their contribution to gestational diabetes and racial disparities. T... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
06/14/2023
Locations: Sanford Health, Sioux Falls, South Dakota
Conditions: Pregnancy
PTSD, AUD, and Interpersonal Conflict: Within-person Associations
Recruiting
The present study seeks to increase understanding of Alcohol Use Disorder (AUD) and Posttraumatic Stress Disorder (PTSD) among veterans, an important public health concern. We will study the effects of regulatory deficits and sleep disturbance on the dynamic course of PTSD and AUD. The study will investigate whether a short, computerized training in the laboratory will alter maladaptive response biases and reduce associations between sleep disturbance, affect and behavioral dysregulation, AUD sy... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
05/08/2023
Locations: Sioux Falls VA Health Care System, Sioux Falls, South Dakota
Conditions: Stress Disorders, Post-Traumatic, Alcoholism
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with a JAK inhibitor. Inhibition of MDM2 is a novel mechanism of action in MF.
This study will be conducted in 2 phases. Phase 2 will determine the KRT-232 recommended dose and dosing schedule; Phase 3 will test KRT-232 vs Best Available Therapy (BAT). Patients in the Phase 3 part of the study will be randomized 2:1 to receive ei... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2023
Locations: Avera Cancer Institute, Sioux Falls, South Dakota
Conditions: Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Post-Essential Thrombocythemia MF (Post-ET-MF)
Contoura With Phorcides Compared to Wavefront Optimized LASIK
Recruiting
Comparing post-operative visual acuity and patient reported satisfaction between Contoura with Phorcides and WaveLight Wavefront Optimized.
Gender:
All
Ages:
Between 21 years and 38 years
Trial Updated:
04/24/2023
Locations: Vance Thompson Vision, Sioux Falls, South Dakota
Conditions: Myopia, Astigmatism
Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction
Recruiting
This phase II trial studies the side effects of intraoperative electron beam radiotherapy boost and to see how well it works in treating patients with stage I-II breast cancer undergoing surgery with reconstruction. Giving a single dose of electron beam radiation to the tumor cavity during the breast surgery before reconstruction may be a better way to kill tumor cells and shrink tumors.
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/07/2023
Locations: Avera Cancer Institute, Sioux Falls, South Dakota
Conditions: Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer
Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer
Recruiting
This phase II Lung-MAP treatment trial tests whether carboplatin and pemetrexed with or without selpercatinib works to shrink tumors in patients with RET fusion-positive non-small cell lung cancer that is stage IV or has not responded to previous RET directed therapy. Chemotherapy drugs, such as carboplatin and pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Selpercatinib may st... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/28/2023
Locations: Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota +1 locations
Conditions: Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer
Recruiting
This study will evaluate the efficacy and safety of niraparib and novel treatment combinations of niraparib as described within each cohort-specific supplement in participants with ovarian, fallopian tube, or primary peritoneal cancer. Cohort A (single arm) includes participants with recurrent ovarian cancer. Cohort B will not be initiated. Cohort C (randomized-2 arms) includes participants with newly diagnosed ovarian cancer.
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/09/2023
Locations: GSK Investigational Site, Sioux Falls, South Dakota
Conditions: Ovarian Neoplasms
CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer
Recruiting
The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Patients will be followed for a minimum of 3 years and up to 5 years for recurrence.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/01/2023
Locations: Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota
Conditions: Colorectal Cancer
myCare-102: Clinical Utility and Usability of Cellworks Singula™ and Cellworks Ventura™ Reports
Recruiting
The purpose of this study is to determine the benefit of Cellworks Singula™ reports on physician and molecular tumor board treatment recommendations across a large set of pan-cancer indications who have already received first-line therapy. The study is also to determine the benefit of Cellworks Ventura™ reports on physician and molecular tumor board treatment recommendations across a large set of relapsed or refractory pan-cancer indications.
The primary objective of this study is to survey phy... Read More
Gender:
All
Ages:
All
Trial Updated:
01/20/2023
Locations: Avera Cancer Institute, Sioux Falls, South Dakota
Conditions: Cancer, Relapsed Cancer, Refractory Cancer
Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors
Recruiting
This is a first-in-human, phase 1, open-label, dose-escalation study of STI-6643 administered by intravenous infusion in subjects with a relapsed/refractory advanced solid tumor.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/12/2023
Locations: Sanford Health, Sioux Falls, South Dakota
Conditions: Solid Tumor, Relapsed Solid Neoplasm, Refractory Tumor
253 - 264 of 276